Nextbiotix, a Dijon, France-based microbiome company, raised €7m (approx. $8m) in Series A funding.
The round was led by Auriga Partners, with participation from Sofimac Innovation, Cap Innov’Est, INRA and Biocodex.
The company intends to use the funds to develop a bacterial treatment for inflammatory bowel diseases.
Co-founded in December 2016 by Harry Sokol, Philippe Langella and Patrick Gervais, alongside with healthtech entrepreneur Michael Chekroun and Benjamin Hadida, current CEO, Nextbiotix is developing microbiome-based therapies using single microbial strains that interact with human cells in the gut.
The company also has offices in Paris.